Milestone Pharmaceuticals Enrolls First EU Patient in Phase 3 Etripamil Trial in Atrial Fibrillation

MT newswire2026/10/09 12:43

08:43 AM EDT, 10/09/2026 (MT Newswires) -- Milestone Pharmaceuticals (MIST) said Friday that the first European patient has enrolled in its phase 3 pivotal trial of etripamil nasal spray for atrial fibrillation with rapid ventricular rate. The patient was enrolled at a site in the Netherlands, the company said. The trial targets to enroll about 150 patients, Milestone said, adding that enrollment is also underway in the US and Canada. The company said the study is evaluating a 70 mg repeat-dose regimen of etripamil, which is approved in the US as Cardamyst for paroxysmal supraventricular tachycardia. Milestone Pharmaceuticals shares were up 4.6% in premarket activity Friday.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

The central bank has increased its gold reserves for 24 consecutive months, with October’s increase hitting a record high for the period.

新浪财经•2026/11/09 05:37

Trader Gu Jingci: November 9 Bitcoin/Ethereum Trading Strategy and Market Analysis

AiCoin•2026/11/09 05:35

Dow Jones Top Energy Headlines at 12 AM ET: Oil Futures Slide As Market Holds Out Hopes for Middle East Diplomacy | Energy ...

Dow Jones•2026/11/09 05:00

United States Dollar Index remains subdued as lower oil prices ease inflation pressure

FXStreet•2026/11/09 04:54